Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension.
CM, P., L, G., G, C., I, G., P, R., E, D.d.l.R., F, S., F, P., S, B., & M, S. (2026). Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension.. PloS one. https://doi.org/10.1371/journal.pone.0356364
CM P, L G, G C, I G, P R, E DdlR, et al. Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension.. PloS one. 2026; doi: 10.1371/journal.pone.0356364
CM P, L G, G C, et al. Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension.[J]. PloS one. 2026. DOI: 10.1371/journal.pone.0356364.
@article{cm2026,
author = {Pilard CM and Gassiat L and Cardouat G and Gauthereau I and Robillard P and Dumas-de-la-Roque E and Sauvestre F and Pelluard F and Berenguer S and Sarreau M},
title = {Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension.},
journal = {PloS one},
year = {2026},
doi = {10.1371/journal.pone.0356364},
note = {PMID: 42636229},
}
TY - JOUR AU - Pilard CM AU - Gassiat L AU - Cardouat G AU - Gauthereau I AU - Robillard P AU - Dumas-de-la-Roque E AU - Sauvestre F AU - Pelluard F AU - Berenguer S AU - Sarreau M TI - Role of connexin 43 in hyperoxia-induced bronchopulmonary dysplasia and associated pulmonary hypertension. T2 - PloS one PY - 2026 DO - 10.1371/journal.pone.0356364 AN - PMID:42636229 ER -
Premature infants frequently require oxygen supplementation due to lung immaturity, exposing them to the risk of bronchopulmonary dysplasia (BPD), a chronic lung disease characterized by arrested alveolar growth and inflammation. Connexin 43-dependent gap junctions (Cx43-GJ) regulate intercellular communication during lung development and inflammatory responses, but their involvement in BPD remains incompletely defined. This study aimed to assess the contribution of Cx43-GJ in experimental BPD and to evaluate whether selective pharmacological inhibition of Cx43 modulates hyperoxia-induced lung injury and pulmonary hypertension. Newborn rats were exposed to normoxia or hyperoxia (90% O2) for 14 days and treated daily with the Cx43-GJ inhibitor 43Gap26 or vehicle. Human fetal pulmonary artery smooth muscle cells (HfPA-SMC) were exposed to 21% O2 or 60% O2 and treated with or without 43Gap26 for 48 hours. Lung morphology, function, surfactant protein expression, extracellular matrix markers, macrophage phenotype, cytokine secretion, and oxidative stress markers were assessed. In vivo, 43Gap26 reduced hyperoxia-induced Cx43 overexpression and partially improved alveolarization. However, 43Gap26 failed to prevent alterations in lung function, decreased surfactant protein-B expression, extracellular matrix remodeling, macrophage M2 polarization, increased tissue inhibitor of metalloproteinase-1 secretion, pulmonary hypertension, or mortality. Inhibition of Cx43 was also associated with reduced markers of type II alveolar epithelial cell expression. In HfPA-SMC, 43Gap26 did not modify hyperoxia-induced secretion of pro-inflammatory cytokines, despite increased Cx43 expression. Classical markers of oxidative damage were not significantly increased under our experimental conditions, although heme oxygenase-1 expression was elevated. Overall, pharmacological inhibition of Cx43 partially restored alveolar structure but did not prevent major pathological features of experimental BPD or pulmonary hypertension. These findings suggest that Cx43-GJ signaling is involved in the regulation of alveolar structure during hyperoxic lung injury, but its pharmacological inhibition alone is insufficient to prevent the complex structural and vascular alterations characteristic of experimental BPD.